uniQure shares are trading higher amid possible sympathy with Replimune Group after the company announced it will resubmit its RP1 Biologics License Application.

Benzinga Newsdesk www.benzinga.com Positive 93.7%

Neg 0% Neu 0% Pos 93.7%

Comments

No comments yet. Be the first!